According to Gram Research analysis of a 2026 study in The Journal of Nutritional Biochemistry, bergapten, a natural plant compound, improved blood sugar control, reduced liver fat, and lowered inflammation in diabetic mice after eight weeks of treatment. These findings come from animal and cell experiments, so human benefits are not yet proven.
A 2026 study in The Journal of Nutritional Biochemistry looked at whether bergapten, a natural compound found in certain medicinal plants, could help with type 2 diabetes. Gram Research analysis of this work shows that diabetic mice given bergapten for eight weeks had better blood sugar control, improved glucose tolerance, and more sensitive responses to insulin. The treatment also reduced fat buildup in the liver, helped the liver keep its stored sugar, and lowered signs of inflammation. The researchers suggest that a signaling pathway called AKT may play a role in these effects, and they tested this by blocking AKT in liver cells, which weakened several of bergapten’s benefits. These findings come from animal and laboratory experiments, so they cannot yet show whether bergapten would work the same way in people. They do, however, point to a promising direction for future research into type 2 diabetes and related liver problems.
Key Statistics
A 2026 study published in The Journal of Nutritional Biochemistry found that eight weeks of bergapten treatment lowered high blood sugar and improved glucose tolerance in mice with diet-induced type 2 diabetes.
The same 2026 animal study reported that bergapten reduced fat buildup in the liver and preserved the liver’s stored sugar reserves, while also lowering the activity of inflammatory genes including TNF-α, IL-1β, and IL-6.
In laboratory tests on insulin-resistant liver cells, blocking the AKT signaling pathway with the drug MK-2206 weakened several of the effects of bergapten, according to a 2026 study in The Journal of Nutritional Biochemistry.
The Quick Take
- What they studied: Can bergapten, a natural compound from some traditional Chinese medicinal plants, help control type 2 diabetes, and how might it work inside the body?
- Who participated: The main experiments used mice that were given a high-fat diet and a drug that damages insulin-producing cells, which caused diabetes-like conditions. Separate lab tests used a liver cell line that was made insulin-resistant. The number of animals was not specified in the study summary.
- Key finding: After eight weeks, bergapten lowered high blood sugar and blood fats, improved glucose tolerance, reduced liver fat, and eased inflammation in diabetic mice. The researchers also found that blocking a signaling pathway called AKT weakened several of these effects, which suggests AKT is involved.
- What it means for you: These results are promising but preliminary. They come from mice and cell studies, so they do not show that bergapten is safe or effective for people with diabetes. Anyone managing diabetes should keep following their doctor’s advice and should not start taking bergapten supplements based on this research.
The Research Details
The researchers first created diabetes-like conditions in mice by feeding them a high-fat diet and giving them a drug called streptozotocin, which damages the cells that make insulin. Some mice then received bergapten for eight weeks, and their blood sugar, blood fats, glucose tolerance, and insulin response were measured and compared with untreated mice. Afterward, the team examined liver tissue under a microscope and measured levels of inflammatory signals and stress-related proteins.
To explore how bergapten might work, the team also used computer-based network analysis to find biological pathways that could be involved. They then used molecular docking, a computer simulation that predicts how a molecule might fit onto a protein, to estimate whether bergapten could bind to a protein called AKT1. Separately, they treated a liver cell line with glucosamine to make it resistant to insulin, then added bergapten, and in some tests also added MK-2206, a drug that blocks AKT.
This step-by-step approach helps show how a compound might work, not just whether it changes blood sugar. Using both whole animals and cells makes it possible to connect effects seen in the body with what happens inside individual liver cells.
Testing in a living animal shows whether a compound has effects across the whole body, including blood sugar, weight-related fat, and the liver. Testing in cells then helps narrow down the exact mechanism. Blocking AKT with a drug is a useful check, because if the benefits disappear when a pathway is blocked, that is a clue that the pathway is part of how the compound works.
The study uses several complementary methods, including animal testing, tissue analysis, cell experiments, and computer modeling, which supports the findings from different angles. However, the study summary does not report how many animals were used, how they were assigned to groups, or whether the results were statistically checked in detail. Animal models of diabetes also do not fully match human disease, so results often do not carry over directly to people. Because the paper is an early-stage laboratory study, it is best viewed as a starting point rather than proof.
What the Results Show
The most important result was that bergapten improved the way the body handles blood sugar. In mice with diabetes-like conditions, bergapten lowered high blood sugar and abnormal blood fats. It also restored glucose tolerance, which is the body’s ability to clear sugar from the blood after eating, and improved insulin sensitivity, meaning cells responded better to insulin.
The liver showed clear changes as well. Bergapten reduced hepatic steatosis, the buildup of fat inside liver cells that is common in people with type 2 diabetes. It also preserved hepatic glycogen, the stored form of sugar the liver keeps for energy, which suggests the liver was better able to manage its sugar reserves.
The researchers also looked at the molecular changes behind these effects. Bergapten increased a marker called GSK3β Ser9 phosphorylation, which is linked to better control of sugar storage. It reduced signals from inflammatory proteins IκBα and NF-κB, and lowered the activity of genes for the inflammatory messengers TNF-α, IL-1β, and IL-6. These messengers are known to make insulin resistance worse when they are too active.
Finally, bergapten reduced levels of GRP78 and IRE1α, two proteins that rise when cells experience endoplasmic reticulum stress, a type of cellular strain that can contribute to insulin resistance. Together, these findings suggest bergapten may calm several stress and inflammation pathways at once, although the study does not prove these changes cause the improvements in blood sugar.
Computer-based network analysis pointed to the PI3K-AKT signaling pathway as a likely route of action. This pathway helps control how cells use sugar and respond to insulin, so its involvement fits with the overall results. The molecular docking simulation suggested that bergapten could bind to AKT1, but computer predictions are only a rough guide and need laboratory confirmation.
In the insulin-resistant liver cell experiments, blocking AKT with MK-2206 weakened several of bergapten’s effects. This is an important clue that AKT is part of the mechanism, though the researchers describe their conclusion carefully rather than claiming AKT is the sole driver.
Many natural plant compounds have been studied for blood sugar and liver health, and the general idea that anti-inflammatory and stress-reducing compounds can support insulin sensitivity is well established. Bergapten itself has been studied for other conditions, so this study extends its possible use into type 2 diabetes. The focus on AKT signaling connects this work to a large body of research on how insulin signals move through cells.
The most important limitation is that all the main experiments were done in mice and in cultured cells, not in people. Animal results often differ from human results because of differences in metabolism, diet, and disease development. The study summary also does not report how many animals were used, how long the effects lasted beyond eight weeks, or what dose was given compared with doses people might take. Computer predictions of how bergapten binds to AKT1 are only estimates. Finally, the AKT-blocking experiments were done in one liver cell line, so the results may not apply to all tissues or to whole living bodies.
The Bottom Line
Based on this study alone, there is not enough evidence to recommend bergapten for people with type 2 diabetes. Confidence is low at this stage because the findings come from animal and cell experiments. The results are strong enough to justify further studies, including careful human trials that test safety, correct doses, and whether blood sugar and liver health improve in people. Anyone interested in this compound should discuss it with a doctor first, since some plant compounds can interact with medications.
Researchers studying diabetes, liver disease, and natural compounds should pay close attention, since the study points to a possible new direction. People with type 2 diabetes or fatty liver disease may find it interesting, but should not change their treatment based on these results. People who take diabetes medicines should be especially careful about using any supplement without medical guidance. People without diabetes do not need to act on this research.
Realistic expectations are measured in years, not weeks. Even if bergapten proves useful, it would need to pass several stages of human testing for safety and effectiveness before doctors could consider it. The mice in this study took eight weeks to show changes, but human bodies respond differently, and any real benefit would need to be confirmed through long-term clinical trials.
Frequently Asked Questions
Does bergapten help with type 2 diabetes?
Early research suggests it may. In a 2026 study, diabetic mice given bergapten for eight weeks showed better blood sugar control, improved insulin sensitivity, and less liver fat. These results come from animal and cell studies, so human effects have not been tested yet.
What is bergapten and where does it come from?
Bergapten is a natural compound found in some traditional Chinese medicinal herbs. Researchers have studied it for several health conditions. Its effects on type 2 diabetes were examined in mice and liver cells in a 2026 study published in The Journal of Nutritional Biochemistry.
Can I take bergapten supplements to lower my blood sugar?
No human studies have yet shown that bergapten lowers blood sugar safely or effectively. The current evidence comes from mice and lab cells. Anyone with diabetes should talk with their doctor before using any supplement, especially if they take diabetes medication.
How does bergapten affect the liver in diabetes?
In diabetic mice, bergapten reduced fat buildup in liver cells and helped the liver keep its stored sugar. It also lowered inflammatory signals and stress-related proteins. Researchers suggest these changes may be linked to the AKT signaling pathway, though this is not yet confirmed.
Want to Apply This Research?
- Track fasting blood sugar readings, if available from a glucose meter or lab test, along with post-meal readings at the same time each week. Record these numbers alongside any changes in diet, activity, or medication, and share the log with your healthcare provider.
- Use the app to set a reminder for a daily walk after your largest meal, and log how many minutes you complete. Walking after meals is a well-supported habit for helping the body manage blood sugar. Pair this with logging whole, fiber-rich foods so you can see patterns over time.
- Keep a monthly summary of blood sugar readings, weight, waist measurements, and activity minutes so trends are easy to spot. Review the data with your doctor at regular checkups. If you ever consider a new supplement such as bergapten, log its start date and any changes in your numbers so you and your doctor can judge its effect.
This article summarizes an early-stage study conducted in mice and laboratory cells, not in humans. The findings do not show that bergapten is safe or effective for treating diabetes in people. Do not start, stop, or change any medication or supplement based on this research. Talk with a qualified healthcare provider about any questions regarding diabetes, blood sugar, or liver health.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.